本次会议是否有否决议案：无 证券代码：600671 证券简称：天目药业 公告编号：临 2025-040 杭州天目山药业股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 9 月 12 日 (二) 股东大会召开的地点：浙江省杭州市博亚时代中心 1803 会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 77 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 54,078,489 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 44.4071 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议由董事会提议召开，由董事长刘加勇先生通过现场方式主持，记名 投票方式表决。会议采用现场投票和网络投票相结合的方式进行。会 ...

Core Points - The company is holding its third extraordinary general meeting of shareholders in 2025 on September 12, 2025, to discuss key governance changes [1][2] - The main proposals include the cancellation of the supervisory board, amendments to the articles of association, and the establishment of new governance systems [3][4][6] Proposal Summaries Proposal 1: Cancellation of the Supervisory Board and Amendment of Articles of Association - The company proposes to cancel the supervisory board, transferring its powers to the audit committee of the board of directors, and amend the articles of association accordingly [4][5] - Changes will include replacing terms related to the supervisory board with references to the audit committee to ensure compliance with the revised Company Law [4] Proposal 2: Cancellation of the Supervisory Board and Abolition of Supervisory Meeting Rules - The company aims to abolish the supervisory meeting rules in conjunction with the cancellation of the supervisory board, with the audit committee assuming the relevant responsibilities [5] Proposal 3: Revision and Establishment of Company Governance Systems - The company plans to revise and establish certain governance systems to enhance operational standards and governance levels, in line with the latest legal and regulatory requirements [6]

杭州天目山药业股份有限公司 2025 年第三次临时股东大会会议资料 杭州天目山药业股份有限公司 2025 年第三次临时股东大会 会议资料 中国•杭州 二〇二五年九月十二日 1 / 8 杭州天目山药业股份有限公司 2025 年第三次临时股东大会会议资料 目 录 | 2025 年第三次临时股东大会会议议程 | 3 | | --- | --- | | 2025 年第三次临时股东大会须知 | 4 | | 议案一：关于取消监事会并修订《公司章程》的议案 | 5 | | 议案二：关于取消监事会并废止《监事会议事规则》的议案 | 7 | | 议案三：关于修订、制定部分公司治理制度的议案 | 8 | 2 / 8 杭州天目山药业股份有限公司 2025 年第三次临时股东大会会议资料 2025年第三次临时股东大会会议议程 会议召开方式：本次股东大会采用现场会议和网络投票相结合的方式，网络投票 系统为上海证券交易所股东大会网络投票系统 会议召集人：董事会 会议主持人：公司董事长 会议议程： 3 / 8 现场会议时间：2025年9月12日下午14:00 现场会议地点：浙江省杭州市博亚时代中心1803会议室 一、大会主持人介绍到会股东及 ...

Core Viewpoint - Tianmu Pharmaceutical announced the appointment of Mr. Han Tongmin as the new Deputy General Manager of the company [2] Group 1 - The appointment was officially disclosed in an announcement made by Tianmu Pharmaceutical on the evening of September 2 [2]

Group 1 - Tianmu Pharmaceutical announced the resignation of Wang Yihui from the positions of director, member of the strategic committee, and financial director due to work relocation [1] - The company appointed Han Tongmin as the new deputy general manager and Dang Guojun as the new financial director, effective from the date of board approval until the end of the current board term [1] - Huang Junde was elected as a member of the compensation and assessment committee, also until the end of the current board term [1] Group 2 - For the fiscal year 2024, Tianmu Pharmaceutical's revenue composition is as follows: health products 31.37%, pharmaceutical circulation products 21.97%, service category 19.74%, raw materials 12.64%, and traditional Chinese medicine 11.84% [1] - As of the report date, Tianmu Pharmaceutical has a market capitalization of 2.3 billion yuan [1]

Core Viewpoint - Tianmu Pharmaceutical announced the approval of multiple proposals, including the appointment of a new vice president, during the 15th meeting of its 12th board of directors [2] Group 1 - The company held its 15th meeting of the 12th board of directors on September 2 [2] - The board approved the proposal regarding the appointment of a vice president [2]

Core Viewpoint - The announcement details the resignation of Wang Yihui, the company's director and CFO, due to job relocation, and the subsequent appointments of new senior management personnel and adjustments to the board's specialized committees [1][2]. Group 1: Resignation of Senior Management - Wang Yihui submitted her resignation as a director, strategic committee member, and CFO, effective immediately upon delivery to the board [1][2]. - Her resignation will not affect the board's minimum number of members or the company's daily operations, and she has no outstanding commitments or obligations to the company [2]. Group 2: Appointment of New Senior Management - The company appointed Han Tongmin as the new vice president and Dang Guojun as the new CFO, effective from the date of the board's approval [1][2][3]. - Both new appointees have no prior stock holdings in the company and meet all legal and regulatory requirements for their positions [5][6]. Group 3: Adjustment of Board Committees - The board approved the adjustment of its specialized committees, electing non-independent director Huang Junde as a member of the Compensation and Assessment Committee [4]. - The current members of the Compensation and Assessment Committee are Pei Yang (Chairman), Sheng Xiaomeng, and Huang Junde [4].

Group 1 - The company held its 15th meeting of the 12th Board of Directors on September 1, 2025, with all 8 directors present, complying with legal and regulatory requirements [1][2] - The Board approved the appointment of Mr. Han Tongmin as the Vice General Manager, with a term lasting until the end of the current Board's tenure [1][2] - The Board also approved the appointment of Mr. Dang Guojun as the Chief Financial Officer, with a similar term duration [2][3] Group 2 - The Board made adjustments to the members of the Compensation and Assessment Committee, electing non-independent director Mr. Huang Junde as a member [2][3] - The voting results for all resolutions were unanimous, with 8 votes in favor and no votes against or abstentions [2][3]

Group 1 - The core viewpoint of the article is that Tianmu Pharmaceutical (SH 600671) held its 15th meeting of the 12th board of directors on September 1, 2025, to discuss the appointment of a new financial director and other documents [1] - For the fiscal year 2024, the revenue composition of Tianmu Pharmaceutical is as follows: health products account for 31.37%, pharmaceutical circulation products account for 21.97%, service-related products account for 19.74%, raw materials account for 12.64%, and traditional Chinese medicine accounts for 11.84% [1] - As of the time of reporting, the market capitalization of Tianmu Pharmaceutical is 2.3 billion yuan [1]

证券代码：600671 证券简称：天目药业 编号：临 2025-039 | 姓名 | 离任职务 | 离任时间 | 原定任期 | 离任原因 | 是否继续在上 市公司及其控 | 具体职务 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 到期日 | | 股子公司任职 | （如适用） | 毕的公开 | | | | | | | | | 承诺 | | | 董事、战 | | | | | | | | | 略委员会 | | | | | | | | | | 2025 年 8 | 2027 年 6 | | | | | | 王一惠 | 委员和财 | | | 工作调动 | 否 | | 否 | | | | 月 29 日 | 月 12 日 | | | | | | | 务总监职 | | | | | | | | | 务 | | | | | | | 杭州天目山药业股份有限公司 关于董事兼高级管理人员辞职、调整董事会专门委员 会委员及聘任高级管理人员的公告 （一）提前离任的基本情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或 ...